Impact of Cryopreserved Placental Allografts on Biochemical Recurrence in Prostate Cancer.

Publication Title

Cancers (Basel)

Authors

Josh Gottlieb, Department of Urologic Oncology, Providence St. John's Cancer Institute, Santa Monica, CA 90404, USA.Follow
Douglas Hanes, Providence Saint John's Cancer Institute, Santa Monica, CAFollow
Matias A Bustos, Department of Translational Molecular Medicine, John Wayne Cancer Institute (JWCI) at Providence Saint John's Health Center, Santa MonicaFollow
Jane Choe, Department of Urologic Oncology, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, California, USA.Follow
Albert Luu, Providence Saint John's Cancer Institute, Santa Monica, CAFollow
Daniel Seizer, Providence Saint John's Cancer Institute, Santa Monica, CAFollow
Dave SB Hoon, Providence Saint John's Cancer Institute, Santa Monica, CAFollow
Timothy G Wilson, Division of Urologic Oncology, Providence St. John's Health Center, Santa Monica, California, USAFollow

Document Type

Article

Publication Date

8-26-2024

Keywords

california; santa monica; sjci; psjhc

Abstract

BACKGROUND: Human placental allografts are widely used to promote wound healing. Placental (or amniotic membrane/umbilical cord) allografts are placed along the neurovascular bundles during radical prostatectomy to improve continence and erectile function recovery. It is unknown whether placental allografts impact biochemical recurrence (BCR).

METHODS: This was a single-surgeon retrospective study of 566 robotic radical prostatectomies performed from April 2015 to March 2021. The patients were divided into three groups: the negative control, Brand A, and Brand B. Brand A and Brand B were both cryopreserved amniotic membrane (CAM) allografts. A total of 324 cases were included for BCR Kaplan-Meier and risk-adjusted multivariate analyses (362 for continence analysis). In vitro analyses were performed to determine the effect of CAM allografts on prostate cancer (PCa) cell line growth.

RESULTS: For propensity score-matched analysis (adjusting for pre-operative PSA, tumor stage, Gleason Grade, and margin status), (1) the allograft groups did not show differences in time to BCR vs. the negative control group (

CONCLUSIONS: cryopreserved AM allografts (combined or individual brands) did not show a significant effect on BCR but improved continence recovery for PCa patients.

Area of Special Interest

Cancer

Area of Special Interest

Women & Children

Specialty/Research Institute

Oncology

Specialty/Research Institute

Urology

Specialty/Research Institute

Surgery

DOI

10.3390/cancers16172973